 PhaseBio Pharmaceuticals Inc NASDAQ: PHAS is voluntarily ending its Phase 2b trial of pemziviptadil PB1046 in pulmonary arterial hypertension PAH. The decision follows COVID-19 impacts on manufacturing, associated drug supply, and enrollment rate in the study. 